Table 3 Patient characteristics
From: Characteristics of ambulatory anticoagulant adverse drug events: a descriptive study
Characteristic | Total events (n = 169) | ADEs (n = 88) | Potential ADEs (n = 81) |
|---|---|---|---|
Age, mean +/- SD | 68.1 +/- 13.2 (range 36-95) | 69.5 +/- 13.5 (range 37-90) | 66.6 +/- 12.8 (range 36-95) |
Insurance, No. (%) | Â | Â | Â |
   Private | 32 (18.9%) | 19 (21.6%) | 13 (16.0%) |
   Private/Medicare | 100 (59.2%) | 52 (59.1%) | 48 (59.3%) |
   Private/Medicaid | 3 (1.8%) | 0 | 3 (3.7%) |
   Medicare | 12 (7.1%) | 7 (8.0%) | 5 (6.2%) |
   Medicare/Medicaid | 14 (8.3%) | 7 (8.0%) | 7 (8.6%) |
   Medicaid | 8 (4.7%) | 3 (3.4%) | 5 (6.2%) |
Indication, No. (%) | Â | Â | Â |
   Atrial fibrillation | 92 (54.4%) | 51 | 41 |
   Deep vein thrombosis | 46 (27.2%) | 19 | 27 |
   Pulmonary embolism | 26 (15.4%) | 13 | 13 |
   Stroke | 23 (13.6%) | 15 | 8 |
   Valve replacement | 23 (13.6%) | 11 | 12 |
   Hypercoagulable | 11 (6.5%) | 3 | 8 |
   Other | 10 (5.9%) | 4 | 6 |
   Indeterminate | 1 (0.6%) | 0 | 1 |
   None | 1 (0.6%) | 1 | 0 |
Duration of warfarin therapy, No. (%) | Â | Â | Â |
   <1 mo | 25 (14.8) | 12 (13.6) | 13 (16.0) |
   1-3 mos | 17 (10.1) | 8 (9.1) | 9 (11.1) |
   4-6 mos | 9 (5.3) | 3 (3.4) | 6 (7.4) |
   7-12 mos | 11 (6.5) | 8 (9.1) | 3 (3.7) |
   1-5 y | 29 (17.2) | 13 (14.8) | 16 (19.8) |
   > 5 y | 25 (14.8) | 15 (17.0) | 10 (12.3) |
   Indeterminate | 52 (30.8) | 28 (31.8) | 24 (29.6) |
   No prescribed warfarin | 1 (0.6) | 1 (1.1) | 0 |
Seen at Duke clinic or hospital within 30 d, No. (%)* | 115 (73.2%) | 52 (65.0%) | 63 (81.8%) |
Anticoag. therapy addressed within 30 d, No. (%)* | 90 (57.3%) | 43 (53.8%) | 47 (61.0%) |